Literature DB >> 22994528

New concepts in pharmacological efficacy at 7TM receptors: IUPHAR review 2.

Terry Kenakin1.   

Abstract

The present-day concept of drug efficacy has changed completely from its original description as the property of agonists that causes tissue activation. The ability to visualize the multiple behaviours of seven transmembrane receptors has shown that drugs can have many efficacies and also that the transduction of drug stimulus to various cellular stimulus-response cascades can be biased towards some but not all pathways. This latter effect leads to agonist 'functional selectivity', which can be favourable for the improvement of agonist therapeutics. However, in addition, biased agonist potency becomes cell type dependent with the loss of the monotonic behaviour of stimulus-response mechanisms, leading to potential problems in agonist quantification. This has an extremely important effect on the discovery process for new agonists since it now cannot be assumed that a given screening or lead optimization assay will correctly predict therapeutic behaviour. This review discusses these ideas and how new approaches to quantifying agonist effect may be used to circumvent the cell type dependence of agonism. This article, written by a corresponding member of the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC-IUPHAR), reviews our current understanding of the interaction of ligands with seven transmembrane receptors. Further information on these pharmacological concepts is being incorporated into the IUPHAR/BPS database GuideToPharmacology.org.
© 2012 The Author. British Journal of Pharmacology © 2012 The British Pharmacological Society.

Mesh:

Substances:

Year:  2013        PMID: 22994528      PMCID: PMC3579279          DOI: 10.1111/j.1476-5381.2012.02223.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  158 in total

1.  The use of stimulus-biased assay systems to detect agonist-specific receptor active states: implications for the trafficking of receptor stimulus by agonists.

Authors:  C Watson; G Chen; P Irving; J Way; W J Chen; T Kenakin
Journal:  Mol Pharmacol       Date:  2000-12       Impact factor: 4.436

2.  The energy landscapes and motions of proteins.

Authors:  H Frauenfelder; S G Sligar; P G Wolynes
Journal:  Science       Date:  1991-12-13       Impact factor: 47.728

Review 3.  Agonist-receptor efficacy. II. Agonist trafficking of receptor signals.

Authors:  T Kenakin
Journal:  Trends Pharmacol Sci       Date:  1995-07       Impact factor: 14.819

4.  The human B1 bradykinin receptor exhibits high ligand-independent, constitutive activity. Roles of residues in the fourth intracellular and third transmembrane domains.

Authors:  L M Leeb-Lundberg; D S Kang; M E Lamb; D B Fathy
Journal:  J Biol Chem       Date:  2000-12-27       Impact factor: 5.157

5.  A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones.

Authors:  J N Kew; G Trube; J A Kemp
Journal:  J Physiol       Date:  1996-12-15       Impact factor: 5.182

6.  Bone response to intermittent parathyroid hormone is altered in mice null for {beta}-Arrestin2.

Authors:  S L Ferrari; D D Pierroz; V Glatt; D S Goddard; E N Bianchi; F T Lin; D Manen; M L Bouxsein
Journal:  Endocrinology       Date:  2005-02-10       Impact factor: 4.736

7.  Morphine side effects in beta-arrestin 2 knockout mice.

Authors:  Kirsten M Raehal; Julia K L Walker; Laura M Bohn
Journal:  J Pharmacol Exp Ther       Date:  2005-05-25       Impact factor: 4.030

8.  Comparative analysis of the efficacy of A1 adenosine receptor activation of Gi/o alpha G proteins following coexpression of receptor and G protein and expression of A1 adenosine receptor-Gi/o alpha fusion proteins.

Authors:  A Wise; M Sheehan; S Rees; M Lee; G Milligan
Journal:  Biochemistry       Date:  1999-02-23       Impact factor: 3.162

9.  Functionally selective M1 muscarinic agonists. 3. Side chains and azacycles contributing to functional muscarinic selectivity among pyrazinylazacycles.

Authors:  J S Ward; L Merritt; D O Calligaro; F P Bymaster; H E Shannon; B D Sawyer; C H Mitch; J B Deeter; S C Peters; M J Sheardown; P H Olesen; M D Swedberg; P Sauerberg
Journal:  J Med Chem       Date:  1995-09-01       Impact factor: 7.446

10.  Identification of three separate guanine nucleotide-binding proteins that interact with the delta-opioid receptor in NG108-15 neuroblastoma x glioma hybrid cells.

Authors:  S C Roerig; H H Loh; P Y Law
Journal:  Mol Pharmacol       Date:  1992-05       Impact factor: 4.436

View more
  60 in total

1.  Identification of the first biased NPS receptor agonist that retains anxiolytic and memory promoting effects with reduced levels of locomotor stimulation.

Authors:  Stewart D Clark; Terrence P Kenakin; Steven Gertz; Carla Hassler; Elaine A Gay; Tiffany L Langston; Rainer K Reinscheid; Scott P Runyon
Journal:  Neuropharmacology       Date:  2017-03-03       Impact factor: 5.250

Review 2.  Superagonism at G protein-coupled receptors and beyond.

Authors:  R Schrage; A De Min; K Hochheiser; E Kostenis; K Mohr
Journal:  Br J Pharmacol       Date:  2015-10-24       Impact factor: 8.739

3.  Biased ligand quantification in drug discovery: from theory to high throughput screening to identify new biased μ opioid receptor agonists.

Authors:  David Winpenny; Mellissa Clark; Darren Cawkill
Journal:  Br J Pharmacol       Date:  2016-03-01       Impact factor: 8.739

Review 4.  Identifying ligands at orphan GPCRs: current status using structure-based approaches.

Authors:  Tony Ngo; Irina Kufareva; James Lj Coleman; Robert M Graham; Ruben Abagyan; Nicola J Smith
Journal:  Br J Pharmacol       Date:  2016-03-05       Impact factor: 8.739

5.  Evolving pharmacology of orphan GPCRs: IUPHAR Commentary.

Authors:  Anthony P Davenport; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

Review 6.  Proteinases, their receptors and inflammatory signalling: the Oxford South Parks Road connection.

Authors:  M D Hollenberg
Journal:  Br J Pharmacol       Date:  2015-03-17       Impact factor: 8.739

7.  Disruption of the Na+ ion binding site as a mechanism for positive allosteric modulation of the mu-opioid receptor.

Authors:  Kathryn E Livingston; John R Traynor
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-08       Impact factor: 11.205

Review 8.  Allostery at opioid receptors: modulation with small molecule ligands.

Authors:  Kathryn E Livingston; John R Traynor
Journal:  Br J Pharmacol       Date:  2017-06-07       Impact factor: 8.739

Review 9.  Efficacy and ligand bias at the μ-opioid receptor.

Authors:  E Kelly
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

10.  Constitutive Desensitization of Opioid Receptors in Peripheral Sensory Neurons.

Authors:  Laura C Sullivan; Teresa S Chavera; Raehannah J Jamshidi; Kelly A Berg; William P Clarke
Journal:  J Pharmacol Exp Ther       Date:  2016-09-22       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.